Definium Therapeutics
DFTX
155 hedge funds and large institutions have $14.9M invested in Definium Therapeutics in 2022 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 26 increasing their positions, 41 reducing their positions, and 51 closing their positions.
119% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $842K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.4% less ownership
Funds ownership: 0.76% → 0.36% (-0.4%)
4% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 51
3% less funds holding
Funds holding: 159 → 155 (-4)
37% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 41
72% less capital invested
Capital invested by funds: $53.6M → $14.9M (-$38.6M)
Top Buyers
| 1 |
Millennium Management
New York
|
+$3.91M |
| 2 |
E
Ergoteles
New York
|
+$917K |
| 3 |
LPL Financial
San Diego,
California
|
+$653K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$457K |
| 5 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$449K |
Top Sellers
| 1 |
BlackRock
New York
|
-$13.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.37M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$2.52M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.41M |
DFTX Hedge Fund Activity: Q2 2022 in Review
155 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2022, worth a combined $14.9M — down 72% from $53.6M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of DFTX and 49 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 26 added.
The largest buyer was Millennium Management, adding an estimated $3.91M. The largest seller was BlackRock, cutting an estimated $13.7M.
- 155 institutional investors held Definium Therapeutics (DFTX) as of Q2 2022, down from 159 in Q1 2022.
- Funds reported $14.9M of Definium Therapeutics stock for Q2 2022, down 72% quarter-over-quarter.
- 49 funds opened new Definium Therapeutics positions in Q2 2022 and 51 closed out, a net change of -2 holders.
- The largest Definium Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $3.91M added.
- The largest Definium Therapeutics seller in Q2 2022 was BlackRock, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2022.